Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

628 questions · 651 findings · 39 reviews · Skin

No studies found 167 · 25.7%GRADE not reported 47 · 7.2%Very low 80 · 12.3%Low 139 · 21.4%Moderate 174 · 26.7%High 44 · 6.8%

Secukinumab vs placebo

Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis

Secukinumab probably leads to higher proportion of participants with a 50% reduction in disease severity compared with placebo (moderate certainty).

1 finding from 1 review

Secukinumab vs placebo

Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Secukinumab vs placebo

Proportion of participants with adverse effects in the short term ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Serlopitant 1 mg vs placebo

Sleep disturbances: number of participants with insomnia · chronic pruritus of unknown origin

It is very uncertain whether serlopitant 1 mg changes sleep disturbances: number of participants with insomnia compared with placebo (very low certainty).

1 finding from 1 review

Serlopitant 0.25 mg vs placebo

Sleep disturbances: number of participants with insomnia · chronic pruritus of unknown origin

It is very uncertain whether serlopitant 0.25 mg changes sleep disturbances: number of participants with insomnia compared with placebo (very low certainty).

1 finding from 1 review

Serlopitant 5 mg vs placebo

Sleep disturbances: number of participants with insomnia · chronic pruritus of unknown origin

It is very uncertain whether serlopitant 5 mg changes sleep disturbances: number of participants with insomnia compared with placebo (very low certainty).

1 finding from 1 review